Fertility and Sterility
Volume 88, Issue 1 , Pages 237-239 , July 2007

Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles

  • Bruce S. Shapiro, M.D.

      Affiliations

    • Fertility Center of Las Vegas, Las Vegas, Nevada
    • Department of Obstetrics and Gynecology, University of Nevada School of Medicine, Las Vegas, Nevada
    • Corresponding Author InformationReprint requests: Bruce Shapiro, M.D., Fertility Center of Las Vegas, 8851 West Sahara Avenue, #100, Las Vegas, Nevada 89117 (FAX: 702-254-1213).
    • ,
  • Said T. Daneshmand, M.D.

      Affiliations

    • Fertility Center of Las Vegas, Las Vegas, Nevada
    • Department of Obstetrics and Gynecology, University of Nevada School of Medicine, Las Vegas, Nevada
    • ,
  • Forest C. Garner, M.S.

      Affiliations

    • Fertility Center of Las Vegas, Las Vegas, Nevada
    • Department of Obstetrics and Gynecology, University of Nevada School of Medicine, Las Vegas, Nevada
    • ,
  • Martha Aguirre, Ph.D.

      Affiliations

    • Fertility Center of Las Vegas, Las Vegas, Nevada
    • ,
  • Richard Ross, M.S.

      Affiliations

    • Fertility Center of Las Vegas, Las Vegas, Nevada

Received 20 July 2006 ,Revised 30 October 2006 ,Accepted 16 November 2006.

References 

  1. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2003;80:1309–1314
  2. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R, Morris S. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril. 2005;84:93–98
  3. Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it!. Hum Reprod. 2000;15:2266–2267
  4. Kol S. Luteolysis induced by a gonadotropin releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1–5
  5. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260–1265
  6. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod. 1995;10:811–814
  7. Halme J, Toma SK, Talbert LM. A case of severe ovarian hyperstimulation in a healthy oocyte donor. Fertil Steril. 1995;64:857–859
  8. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–1220
  9. Kolibianakis EM, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–2892
  10. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–168

PII: S0015-0282(06)04572-9

doi: 10.1016/j.fertnstert.2006.11.069

Fertility and Sterility
Volume 88, Issue 1 , Pages 237-239 , July 2007

Article Tools